- Home
- MAIA vs ANL Comparison
MAIA vs ANL Comparison
Compare MAIA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAIA | ANL |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 52.0M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MAIA | ANL |
|---|---|---|
| Price | $1.23 | $0.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 449.7K | 13.2K |
| Earning Date | 11-07-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.88 |
| 52 Week High | $2.74 | $2.99 |
Technical Indicators
Market Signals| Indicator | MAIA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 22.30 |
| Support Level | $1.07 | $1.32 |
| Resistance Level | $1.25 | $1.59 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 61.02 | 5.70 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.